

Company Announcement no. 23/2007

To: OMX Nordic Exchange

Hørsholm, Denmark, September 10, 2007

LifeCycle Pharma A/S – Report Pursuant to the Danish Securities Trading Act, Section 28(a)

Summary: Report of transactions in LifeCycle Pharma shares and related securities by persons discharging managerial responsibilities and persons/companies closely associated with these.

Hørsholm, Denmark, September 10, 2007; Pursuant to the Danish Securities Trading Act, Section 28(a), LifeCycle Pharma A/S (OMX:LCP) is required, on a daily basis, to make public transactions in LifeCycle Pharma shares and related securities by persons discharging managerial responsibilities and persons/companies closely associated with these.

Name	Michael Wolff Jensen
Reason for reporting	Chief Financial Officer
Issuer and ID code/ISIN	LifeCycle Pharma A/S / DK0060048148
Type of transaction	Subscription of shares through exercise of warrants
Date of transaction	September 10, 2007
Relevant market	OMX, Nordic Exchange
Number of traded securities	100,000
Market value (subscription price)	DKK 738,250

About LifeCycle Pharma A/S ("LCP A/S"):

LCP A/S, headquartered in Hørsholm, Denmark, is an emerging specialty pharmaceutical company focused on developing and commercializing a portfolio of innovative products in therapeutic areas such as cholesterol management, hypertension, organ transplantation and autoimmune diseases. LCP's proprietary MeltDose® technology, offers lower dosing, reduced side effects, improved safety and patient compliance, and reduced product development costs and times. LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and hypertriglyceridemia, is LCP's first FDA approved product (approved in August 2007). LCP is listed on the OMX Nordic Exchange under the trading symbol (OMX:LCP). For further information, please visit www.lcpharma.com.

Contact:

Michael Wolff Jensen

Executive Vice President and CFO

Tel. +45 70 33 33 00

Mob. +45 40 74 62 44

Email. mwj@lcpharma.com

---oo0oo---

